High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin’s lymphoma

Autor: C H Weaver, B Zhen, Lee S. Schwartzberg, J West, S Rhinehart, Buckner Cd, WH West

Publikováno v: Bone Marrow Transplantation. 21:383-389

Forty-nine patients with low-grade non-Hodgkin's lymphoma (NHL) received high-dose chemotherapy (HDC) with busulfan and cyclophosphamide (BUCY) or carmustine, etoposide, cytarabine and CY (BEAC) followed by unpurged autologous peripheral blood stem (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae3fd8a662f9c7bfd3c0edb841087303
https://doi.org/10.1038/sj.bmt.1701101

Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses

Autor: Raefsky E, Kalman L, R Leff, WH West, FA Greco, B McAneny, Buckner Cd, C H Weaver, M Magee, J Hainsworth, T. Alberico, Lee S. Schwartzberg, R Birch

Publikováno v: Bone Marrow Transplantation. 19:661-670

Summary: complete remission (CR) rates (40‐50%) with median overall survivals of 18‐24 months and progression-free survivals (PFS) of 12‐25% in patients with breast cancer We investigated the outcomes of patients with breast cancer undergoing i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0913572075e88adf15a955e52c4398b
https://doi.org/10.1038/sj.bmt.1700728

Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: outpatient administration in community cancer centers

Autor: Carter P, Rymer W, Blanco R, F Wittlin, WH West, Lee S. Schwartzberg, Buckner Cd, R Leff, Campos L, F A Greco, Robert Birch, John D. Hainsworth, C H Weaver, M Mangum, Tauer Kw, Raefsky E

Publikováno v: American journal of clinical oncology. 21(5)

The authors determined outcomes for patients with localized high-risk breast cancer undergoing sequential outpatient treatment with conventional-dose adjuvant therapy, chemotherapy, and growth factor mobilization of peripheral blood stem cells (PBSC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb1810af907688cad6b50925d1e2a49f
https://pubmed.ncbi.nlm.nih.gov/9781614

Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers

Autor: Li W, C H Weaver, WH West, FA Greco, J Hainsworth, Lee S. Schwartzberg, Buckner Cd

Publikováno v: Bone marrow transplantation. 19(7)

Summary: cancer centers. 10‐14 This report describes the 100-day treatment-related mortality (TRM) of the first 1000 consecutive patients receiving high-dose myeloablative chemotherapy High-dose chemotherapy (HDC) with autologous peripheral blood p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa9f12aa6ca6f6e3258d4792884daf27
https://pubmed.ncbi.nlm.nih.gov/9156243

Earlier surgery improves outcomes from painful chronic pancreatitis.

Autor: Ke N; Department of Pancreatic Surgery Division of General Practice Department of Integrated Traditional Chinese and Western Medicine (WH), West China Hospital, Sichuan University, Chengdu, China NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK Department of Surgery (JAW), University of Auckland, Auckland, New Zealand., Jia D, Huang W, Nunes QM, Windsor JA, Liu X, Sutton R

Publikováno v: Medicine [Medicine (Baltimore)] 2018 May; Vol. 97 (19), pp. e0651.